TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression

Journal of Clinical Investigation

Volumn 112, Issue 7, 2003, Pages 1116-1124

  Tang, Binwu ^a   Vu, Mary ^a   Booker, Timberly ^a   Santner, Steven J ^b   Miller, Fred R ^b   Anver, Miriam R ^c   Wakefield, Lalage M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL PROLIFERATION; CELL TYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MODEL; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL TRANSFORMATION; DISEASE COURSE; EXPERIMENTAL NEOPLASM; FEMALE; METASTASIS; MOUSE; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0242285692     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318899     Document Type: Article

References (32)

1. Roberts, A.B., and Sporn, M.B. 1990. The transforming growth factors-β. In Handbook of experimental pharmacology. Peptide growth factors and their receptors. M.B. Sporn and A.B. Roberts, editors. Springer-Verlag, Berlin, Germany, 419-472.
2. Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29:117-129.
3. Wakefield, L.M., and Roberts, A.B. 2002. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12:22-29.
4. Massague, J., Blain, S.W., and Lo, R.S. 2000. TGF-β signaling in growth control, cancer, and heritable disorders. Cell. 103:295-309.
5. Fynan, T.M., and Reiss, M. 1993. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncog. 4:493-540.
6. Gold, L.I. 1999. The role for transforming growth factor-β (TGF-β) in human cancer. Crit. Rev. Oncog. 10:303-360.
7. Gobbi, H., et al. 1999. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst. 91:2096-2101.
8. Gobbi, H., et al. 2000. Loss of expression of transforming growth factor β type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology. 36:168-177.
9. Dalal, B.I. Keown, P.A., and Greenberg, A.H. 1993. Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 143:381-389.
10. Walker, R.A., and Dearing, S.J. 1992. Transforming growth factor β1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer. 28:641-644.
11. Gorsch, S.M., Memoli, V.A., Stukel, T.A., Gold, L.I., and Arrick, B.A. 1992. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res. 52:6949-6952.
12. Kong, F.M., et al. 1995. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. 222:155-162.
13. Soule, H.D., et al. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:6075-6086.
14. Dawson, P.J., Wolman, S.R., Tait, L., Heppner, G.H., and Miller, F.R. 1996. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148:313-319.
15. Santner, S.J., et al. 2001. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65:101-110.
16. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90:8392-8396.
17. Tang, B., et al. 1999. Loss of responsiveness to transforming growth factor-β induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res. 59:4834-4842.
18. Schwarz, L.C., Gingras, M.C., Goldberg, G., Greenberg, A.H., and Wright, J.A. 1988. Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic Ha-ras-transformed murine fibroblasts. Cancer Res. 48:6999-7003.
19. Bissell, M.J., and Radisky, D. 2001. Putting tumours in context. Nat. Rev. Cancer. 1:46-54.
20. Liotta, L.A., and Kohn, E.C. 2001. The microenvironment of the tumour-host interface. Nature. 411:375-379.
21. Bottinger, E.P., Jakubczak, J.L., Haines, D.C., Bagnall, K., and Wakefield, L.M. 1997. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57:5564-5570.
22. Amendt, C., Schirmacher, P., Weber, H., and Blessing, M. 1998. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene. 17:25-34.
23. Kanzler, S., et al. 2001. Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene. 20:5015-5024.
24. Hahm, K.B., et al. 2002. Conditional loss of TGF-β signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment. Pharmacol. Ther. 2(Suppl. 16):115-127.
25. Muraoka, R.S., et al. 2002. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109:1551-1559. doi:10.1172/JCI200215234.
26. Oft, M., Heider, K.H., and Beug, H. 1998. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8:1243-1252.
27. Cui, W., et al. 1996. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:531-542.
28. Lee, B.I., et al. 2001. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells. Cancer Res. 61:931-934.
29. Liu, Y., Zhong, X., Li, W., Brattain, M.G., and Banerji, S.S. 2000. The role of Sp1 in the differential expression of transforming growth factor-β receptor type II in human breast adenocarcinoma MCF-7 cells. J. Biol. Chem. 275:12231-12236.
30. Law, B.K., et al. 2002. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol. Cell Biol. 22:8184-8198.
31. Suh, N., et al. 2003. Synthetic triterpenoids enhance transforming growth factor β/Smad signaling. Cancer Res. 63:1371-1376.
32. Yang, Y.A., et al. 2002. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109:1607-1615. doi:10.1172/JCI200215333.